Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Alectinib by F. Hoffmann-La Roche for Inflammatory Myofibroblastic Tumor (IMT): Likelihood of Approval
Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Inflammatory Myofibroblastic Tumor (IMT). According...
Alectinib by F. Hoffmann-La Roche for Central Nervous System (CNS) Tumor: Likelihood of Approval
Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Central Nervous System (CNS) Tumor....
Alectinib by F. Hoffmann-La Roche for High-Grade Glioma: Likelihood of Approval
Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for High-Grade Glioma. According to GlobalData,...
Alectinib by F. Hoffmann-La Roche for Renal Cell Carcinoma: Likelihood of Approval
Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Renal Cell Carcinoma. According to...
Alectinib by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval
Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Solid Tumor. According to GlobalData,...